home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

18.74 -0.03 (-0.16%)

Official Closing Price Updated: 7:00 PM EDT, Apr 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

November 08, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

3 Promising Biotech Stocks Flying Under the Radar ↗

November 08, 2023

Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks.

Via InvestorPlace

Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting

November 07, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Looking Into Takeda Pharmaceutical's Recent Short Interest ↗

November 03, 2023

Via Benzinga

A Look Into Takeda Pharmaceutical Inc's Price Over Earnings ↗

October 19, 2023

Via Benzinga

Earnings Scheduled For October 26, 2023 ↗

October 26, 2023

Companies Reporting Before The Bell • TotalEnergies (NYSE:TTE) is likely to report quarterly earnings at $2.57 per share on revenue of $49.83 billion.

Via Benzinga

Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance

October 26, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Looking Into Takeda Pharmaceutical's Recent Short Interest ↗

October 11, 2023

Via Benzinga

A Look Into Takeda Pharmaceutical Inc's Price Over Earnings ↗

October 04, 2023

Via Benzinga

Alkermes Plummets In Huge Volume. Why One Analyst Says The Reaction Is Overdone. ↗

October 23, 2023

Analysts say Alkermes' drug is clearly active. But investors have concerns.

Via Investor's Business Daily

Week In Review: China's Biopharmas Announce $2.5 Billion In Deals ↗

October 21, 2023

KBP Biosciences sold global rights for its hypertension candidate to Novo Nordisk in an agreement worth up to $1.3 billion. Also, EpimAb Bio sold the rights to use its Fabs-In-Tandem Immunoglobulin...

Via Talk Markets

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

October 18, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda's Crohn's Disease Fistulas Candidates Fall Short In Mid-Stage Study, Settles Tax Dispute With Irish Revenue Commissioners ↗

October 18, 2023

Takeda Pharmaceutical Co Ltd (NYSE: TAK) released topline data from the Phase 3 ADMIRE-CD II study, assessing Alofisel (darvadstrocel) for complex Crohn's Perianal Fistulas (CPF).

Via Benzinga

Looking Into Takeda Pharmaceutical's Recent Short Interest ↗

September 25, 2023

Via Benzinga

Takeda Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire

October 17, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas

October 17, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda’s Dengue Vaccine Recommended by World Health Organization Advisory Group for Introduction in High Dengue Burden and Transmission Areas in Children Ages Six to 16 Years

October 03, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories ↗

October 03, 2023

Benzinga

Via Benzinga

Takeda Withdraws Lung Cancer Drug From US After Failed Confirmatory Trial ↗

October 03, 2023

Following discussions with the FDA, Takeda Pharmaceutical Co Ltd (NYSE: TAK) will voluntarily withdraw Exkivity (mobocertinib)

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 02, 2023

Via Benzinga

Takeda Provides Update on EXKIVITY® (mobocertinib)

October 02, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Can Japan's Economy Continue To Blossom If Bank of Japan Raises Rates? Apparently So. ↗

October 02, 2023

Amid an economic climate of high interest rates in the US and a slumber among China stocks led by a downturn in the property market, Japan’s economy lies in stark contrast to the antipathy that...

Via Benzinga

Topics Economy

HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

September 29, 2023

— Third major market authorization application based on data from the FRESCO-2 global Phase III trial —

From HUTCHMED (China) Limited

Via GlobeNewswire

U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

September 27, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Morphic Therapeutic's Stock Plunges On Monday - Here's Why? ↗

September 25, 2023

Since Friday, Morphic Therapeutic (NASDAQ: MORF) shares have plunged from $47.92 to $26.25 after the company announced the publication of an abstract discussing new EMERALD-1 phase 2a primary results...

Via Benzinga

The Surprise That Prompted Morphic Therapeutic To Dump 52% Over Two Days ↗

September 25, 2023

The company is working on a treatment for ulcerative colitis. But competitive questions linger.

Via Investor's Business Daily

Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

September 25, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Top 4 Health Care Stocks That Should Keep You Up At Night ↗

September 21, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

Takeda Announces FDA Acceptance of NDA Resubmission of TAK-721 (budesonide oral suspension) for the Short-Term Treatment of Eosinophilic Esophagitis (EoE)

September 20, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Is This 250-Year-Old Japanese Big Pharma Giant Selling For Half Price Right Now? ↗

September 18, 2023

When it comes to Big Pharma, Japan’s Takeda Pharmaceutical Co Ltd (NYSE: TAK) is a conservative play that could prove to be a big winner given its cheap valuation and suite of new drugs that portend to...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com